HomeAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Previous close
$33.19
Day range
$33.03 - $34.05
Year range
$19.80 - $35.50
Market cap
1.93B USD
Avg Volume
680.36K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 8.19M | 46.00% |
Operating expense | 31.01M | 9.33% |
Net income | -81.55M | -0.66% |
Net profit margin | -995.84 | 31.06% |
Earnings per share | -1.45 | 1.36% |
EBITDA | -90.72M | -2.14% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 597.99M | -19.10% |
Total assets | 849.71M | -26.20% |
Total liabilities | 105.79M | -7.83% |
Total equity | 743.92M | — |
Shares outstanding | 56.77M | — |
Price to book | 2.53 | — |
Return on assets | -25.76% | — |
Return on capital | -27.16% | — |
Cash Flow
Net change in cash
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Net income | -81.55M | -0.66% |
Cash from operations | -99.87M | -4.92% |
Cash from investing | 124.56M | 116.27% |
Cash from financing | 5.86M | 137.70% |
Net change in cash | 30.56M | 187.01% |
Free cash flow | -72.50M | -10.26% |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
385